Shanghai Institute of Materia Medica Successfully Develops China’s First Quinolone Drug
This article was originally published in PharmAsia News
Executive Summary
Shanghai Institute of Materia Medica has successfully developed China's first quinolone drug - antofloxacin hydrochloride - with intellectual property rights. This represents an achievement under the country's new drug innovation and production program (PharmAsia News, May 11, 2009). With a decade's research and three phases of clinical trials, the drug has gained China's rare Class-I new drug certification and is ready to market. Compared to recent fourth-generation generic quinolone drugs such as prulifloxacin, gemifloxacin and moxifloxacin, the new drug demonstrates advantages in its metabolic characteristics and production costs. It offers long-acting effectiveness of up to 95 percent with the lowest oral dosage for respiratory, urinary and skin infections, making it affordable to the general public. Moreover, its phototoxicity is markedly lower than current similar products including lomefloxacin, sparfloxacin, fleroxacin and ciprofloxacin. (Click here for more - Chinese Language)
You may also be interested in...
China Implements New Drug Innovation And Production Project
China's Ministry of Science and Technology has officially started implementing the new drug innovation and production project to become a pharmaceutical powerhouse (PharmAsia News, Sept. 8, 2008). The country's program with the highest investment, has allocated RMB 5.3 billion ($775 million) for a total of 970 research topics. The first batch of 121 topics with funding of RMB 1 billion has commenced. The second batch of 849 topics which will use the remaining funds has been identified and are ready to go. Sang Guo-wei, chief technology director for the program, stated that chemical drugs will be the emphasis, biopharmaceutical products the highlight and TCM the unique feature. (Click here for more - Chinese language)
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.